tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2025 Dec;21(1):2474772.
doi: 10.1080/21645515.2025.2474772. Epub 2025 Mar 13. Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review
Abby E Rudolph[SUP] 1 [/SUP], Nadine Al Akoury[SUP] 2 [/SUP], Natalija Bogdanenko[SUP] 3 [/SUP], Kristen Markus[SUP] 4 [/SUP], Isabelle Whittle[SUP] 4 [/SUP], Olivia Wright[SUP] 4 [/SUP], Hammam Haridy[SUP] 5 [/SUP], Julia R Spinardi[SUP] 6 [/SUP], John M McLaughlin[SUP] 1 [/SUP], Moe H Kyaw[SUP] 1 [/SUP]
Affiliations
This systematic literature review summarizes the evidence across 56 publications and pre-prints (January 2020-July 2023) with low-risk of bias based on JBI critical appraisal, that report adjusted estimates for the relationship between COVID-19 vaccination and Post-COVID-19 Condition (PCC) by timing of vaccination relative to infection or PCC-onset. Comparisons of adjusted vaccine effectiveness (aVE) against ≥1 PCC (vs. unvaccinated) across study characteristics known to impact PCC burden or VE against other COVID-19 endpoints were possible for 31 studies where vaccination preceded infection. Seventy-seven percent of pre-infection aVE estimates were statistically significant (range: 7%-95%). Statistically significant pre-infection aVE estimates were slightly higher for mRNA (range: 14%-84%) than non-mRNA vaccines (range: 16%-38%) and aVE ranges before and during Omicron overlapped. Our findings suggest that COVID-19 vaccination before SARS-CoV-2 infection reduces the risk of PCC regardless of vaccine type, number of doses received, PCC definition, predominant variant, and severity of acute infections included.
Keywords: COVID-19 vaccine; Post-COVID conditions; SARS-CoV-2; long COVID; post-acute sequelae of SARS-CoV-2 infection; vaccine effectiveness.
. 2025 Dec;21(1):2474772.
doi: 10.1080/21645515.2025.2474772. Epub 2025 Mar 13. Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review
Abby E Rudolph[SUP] 1 [/SUP], Nadine Al Akoury[SUP] 2 [/SUP], Natalija Bogdanenko[SUP] 3 [/SUP], Kristen Markus[SUP] 4 [/SUP], Isabelle Whittle[SUP] 4 [/SUP], Olivia Wright[SUP] 4 [/SUP], Hammam Haridy[SUP] 5 [/SUP], Julia R Spinardi[SUP] 6 [/SUP], John M McLaughlin[SUP] 1 [/SUP], Moe H Kyaw[SUP] 1 [/SUP]
Affiliations
- PMID: 40079963
- DOI: 10.1080/21645515.2025.2474772
This systematic literature review summarizes the evidence across 56 publications and pre-prints (January 2020-July 2023) with low-risk of bias based on JBI critical appraisal, that report adjusted estimates for the relationship between COVID-19 vaccination and Post-COVID-19 Condition (PCC) by timing of vaccination relative to infection or PCC-onset. Comparisons of adjusted vaccine effectiveness (aVE) against ≥1 PCC (vs. unvaccinated) across study characteristics known to impact PCC burden or VE against other COVID-19 endpoints were possible for 31 studies where vaccination preceded infection. Seventy-seven percent of pre-infection aVE estimates were statistically significant (range: 7%-95%). Statistically significant pre-infection aVE estimates were slightly higher for mRNA (range: 14%-84%) than non-mRNA vaccines (range: 16%-38%) and aVE ranges before and during Omicron overlapped. Our findings suggest that COVID-19 vaccination before SARS-CoV-2 infection reduces the risk of PCC regardless of vaccine type, number of doses received, PCC definition, predominant variant, and severity of acute infections included.
Keywords: COVID-19 vaccine; Post-COVID conditions; SARS-CoV-2; long COVID; post-acute sequelae of SARS-CoV-2 infection; vaccine effectiveness.